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Valve selection in the patient with a small aortic root remains a dif-ficult decision for cardiac surgeons. Use of smaller stentedporcine tissue valves in these patients may result in high gradientsand low effective orifice areas.1,2 In some cases, there may beprosthesis-patient mismatch,3 which can result in persistent leftventricular hypertrophy after valve replacement and has been
reported in up to 52% of patients.4 Jin and colleagues5 found no significant regres-
sion of left ventricular hypertrophy in patients after implantation of either stented
tissue valves or mechanical valves, although patients receiving unstented tissue
valves and homografts did demonstrate significant regression. 
Recognition of the potential importance of prosthesis-patient mismatch has led
to interest in developing valve substitutes with improved hemodynamics. Although
much of the recent literature has focused on stentless tissue valves, more tradition-
al valve designs have also evolved to meet this challenge. The St Jude Medical HP
(High Performance) valve was designed to allow supra-annular placement of the
valve through modification of the sewing ring on a standard St Jude Medical valve.
This allows a valve approximately one size larger to be inserted in the same size
aortic root. Intuitively, one would expect this valve to have lower pressure gradients
possibly resulting in better remodeling of the ventricle and more complete regres-
sion of hypertrophy after valve replacement than the standard cuff (SC) St Jude
Medical valve. However, evidence for an improvement in hemodynamics with the
HP valve has been lacking.
In this issue of the Journal, Vitale and coworkers6 report a randomized, multicen-
ter trial comparing the postoperative and 6-month hemodynamics between the St Jude
Medical HP and SC valves. The results are interesting on several levels. When HP and
SC valves were compared at 6 months, both peak and mean pressure gradients were
lower in the 21-mm and 23-mm HP valves than in the SC valves of the same size.
However, effective orifice area did not differ significantly between SC and HP valves.
A possible explanation for this finding lies in the greater cardiac output in the patients
with SC valves in this series, which makes it difficult to draw definitive conclusions
about the hemodynamic superiority of HP over SC valves. At 6 months, both the 21-
mm and 23-mm HP valves demonstrated similarly low gradients (mean gradients of
18.8 and 14.9 mm Hg, respectively) and good effective orifice areas (1.56 cm2 and
1.60 cm2, respectively). These observations suggest that aortic root enlargement pro-
cedures may not be needed to upgrade from a 21-mm HP valve to a 23-mm HP valve
since little additional hemodynamic benefit accrues. Vitale and coworkers also exam-
ined the prevalence of postoperative patient-prosthesis mismatch. In contrast to the
high prevalence in prior reports noted above, no patient in this series had patient-pros-
thesis mismatch according to an effective area index less than 0.9 cm2/m2, slightly
stricter criteria than recommended by Pibarot and Dumesnil.4
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Interestingly, HP valves showed a progressive reduction
in gradient and effective orifice area in serial measurements
after implantation. Since the HP valve is mechanical and
fixed in size, no changes in shape or geometry of the valve
itself are possible. This suggests that there may be remodel-
ing either of the outflow tract or of the distal aorta allowing
a closer matching of valve size with either outflow tract or
aortic size. This late reduction in gradient has been reported
in several previous studies with stentless valves.7,8 Vitale’s
article demonstrates that this late reduction in gradient can
occur in St Jude Medical HP valves and therefore suggests
that the underlying process, whether aortic root remodeling
or left ventricular outflow tract remodeling, can also occur
with bileaflet mechanical valves. 
The present study leaves open several questions for future
investigation. The most important clinical sequela of elevated
aortic valve gradients after valve replacement is incomplete
regression left ventricular hypertrophy. De Paulis and col-
leagues9 have shown that although regression of left ventricu-
lar hypertrophy does occur with bileaflet valves, it may be
incomplete and result in persistent elevations in left ventricu-
lar mass, primarily as a result of residual septal thickening.
The degree of septal thickness has also been shown to be an
independent predictor of mortality in patients with aortic
stenosis.10 It would be of great interest to see comparative data
on changes in left ventricular mass and septal thickness in the
present study and to determine whether left ventricular mass
was more likely to return to normal in the HP group. 
In summary, these findings suggest that the 21-mm and 23-
mm St Jude Medical HP bileaflet mechanical valves are a rea-
sonable choice in the patient with a small aortic root and did
not result in patient-prosthesis mismatch. Ideally, the ultimate
goal of the newer, more hemodynamically efficient valve
designs should be to allow complete regression of hypertro-
phy. Further studies are still required to determine the long-
term effects of both stentless and supra-annular mechanical
valves on left ventricular mass, as well as interactions with
patient factors such as genetics11 and systemic blood pressure. 
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